Polyrizon Ltd.
PLRZ
Positions held
Your positionsPLRZ isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $21.54M | Enterprise value | $2.78M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.77 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -21.4% | ROA | -23.3% | Debt / equity | — |
| Current ratio | 36.37 | Free cash flow | -$2.09M | Analyst recommendation | none | Mean target | — |
| 52w high | $18.20 | 52w low | $2.88 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$3.3M | -$1.5M | -$0.6M | -$0.8M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$5.8M | -$1.3M | -$0.6M | -$0.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
2026-09-22 · Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
2026-09-04 · Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
2026-09-03 · Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
2026-09-02 · Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
2026-08-20 · Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Price (daily)
Full chart · RSI · MACD · patterns